{'fraction_non_alphanumeric': 0.0304, 'fraction_numerical': 0.0, 'mean_word_length': 5.520833333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High flow nasal cannula for continuous positive airway pressure weaning in preterm neonates: A single‐centre experience

High flow nasal cannula therapy (HFNC) is an emerging method of non‐invasive respiratory support therapy for premature infants. Recent evidence around its safety and efficacy for post‐extubation respiratory support is encouraging. However, its effect on long‐term respiratory outcomes is not known. The aim of this study is to determine the effect of HFNC on respiratory outcomes (chronic lung disease (CLD), need for home oxygen) when used to wean babies from continuous positive airway pressure (CPAP).